.png){kind=icon}
返回
Etravirine
.png){kind=icon}
PRE
AI
DOI：10.2165/0003495-200868160-00007.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Etravirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that demonstrates potent in vitro activity against wild-type strains of HIV type I (HIV-1), as well as against numerous strains resistant to available NNRTIs. Furthermore, the potential for resistance to etravirine developing appears to be lower than for first-generation NNRTIs. In treatment-experienced patients infected with HIV-1 with NNRTI resistance, HIV-1 RNA levels of <50 copies/mL (primary endpoint) and <400 copies/mL were achieved by a significantly greater proportion of patients receiving etravirine 200 mg twice daily plus background therapy (BT) than placebo plus BT, according to the planned pooled and individual 24-week analyses of two large, well designed, continuing phase Ill trials (DUET-1 and DUET-2). In the pooled 24-week analysis, patients receiving etravirine plus BT achieved a significantly greater mean reduction in viral load from baseline and a significantly greater mean increase in CD4+ cell counts from baseline than patients receiving placebo plus BT. The pooled and individual findings of the DUET studies at 48 weeks indicate that the efficacy of etravirine is maintained with regard to these endpoints. In the DUET studies, etravirine was generally well tolerated in treatment-experienced patients infected with HIV-1, with a tolerability profile generally similar to that of placebo. Adverse events were mostly of mild or moderate severity.
Keyword:
IMMUNODEFICIENCY-VIRUS TYPE-1
PLACEBO-CONTROLLED TRIAL
EXPERIENCED HIV-1-INFECTED PATIENTS
REVERSE-TRANSCRIPTASE INHIBITORS
HIV-NEGATIVE VOLUNTEERS
DRUG-RESISTANCE
DOUBLE-BLIND
TMC125 ETRAVIRINE
EFFICACY
SAFETY
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.png)
AIDS
OAAI
AIDSIF3.1
OAAI分享收藏An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRT1 resistanceAIDSOAAI
AIDSIF3.1
OAAI分享收藏A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjectsAIDS
AIDSIF3.1
PREAI
分享收藏
查看更多内容